Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK4 | Q16654 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 6/20 | 0.45 |
| ▸ | GRM1 | Q13255 | 6/20 | 0.45 |
| ▸ | BTK | Q06187 | 4/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.45 |
| ▸ | WDR5 | P61964 | 2/20 | 0.44 |
| ▸ | TNF | P01375 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | CDK9 | P50750 | 2/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3993671 | 0.88 | BTK (0.48) | BTKHRH3 | |
| SCHEMBL7030868 | 0.84 | NAMPT (0.49) | PDK4GRM5GRM1BTKNAMPT | |
| SCHEMBL28697188 | 0.83 | PDK4 (0.45) | PDK4GRM5GRM1BTKNAMPT | |
| SCHEMBL12479633 | 0.82 | NAMPT (0.52) | PDK4GRM5GRM1BTKNAMPT | |
| SCHEMBL14648947 | 0.81 | NAMPT (0.51) | PDK4GRM5GRM1BTKNAMPT | |
| SCHEMBL5473100 | 0.81 | NAMPT (0.65) | PDK4GRM5GRM1BTKNAMPT | |
| SCHEMBL17197366 | 0.80 | NAMPT (0.51) | PDK4GRM5GRM1BTKNAMPT | |
| SCHEMBL4770186 | 0.80 | WDR5 (0.51) | PDK4GRM5GRM1NAMPTHTR6 | |
| SCHEMBL25281335 | 0.80 | GRM5 (0.45) | PDK4GRM5GRM1BTKNAMPT | |
| SCHEMBL13177724 | 0.79 | NAMPT (0.47) | PDK4GRM5GRM1NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7473698-B2 | Secondary amino anilinic piperidines as MCH1 antagonists and uses thereof | H. LUNBECK A/S (DK) | 2009-01-06 | — | — | US | disclosed |
| US-7473698-B2 | Secondary amino anilinic piperidines as MCH1 antagonists and uses thereof | H. LUNBECK A/S (DK) | 2009-01-06 | — | — | US | disclosed |
| US-7473698-B2 | Secondary amino anilinic piperidines as MCH1 antagonists and uses thereof | H. LUNBECK A/S (DK) | 2009-01-06 | — | — | US | disclosed |
| EP-1556351-A4 | SECONDARY AMINO ANILINIC PIPERIDINES AS MCH1 ANTAGONISTS AND USES THEREOF | LUNDBECK & CO AS H (DK) | 2007-07-25 | — | — | EP | disclosed |
| US-20050245743-A1 | Secondary amino anilinic piperidines as mch1 antagonists and uses thereof | H. LUNDBECK A/S (DK) | 2005-11-03 | — | — | US | disclosed |
| EP-1556351-A1 | SECONDARY AMINO ANILINIC PIPERIDINES AS MCH1 ANTAGONISTS AND USES THEREOF | H. Lundbeck A/S (DK) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004005257-A1 | SECONDARY AMINO ANILINIC PIPERIDINES AS MCH1 ANTAGONISTS AND USES THEREOF | H. LUNDBECK A/S (DK) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245743-A1 | Secondary amino anilinic piperidines as mch1 antagonists and uses thereof | MCHR1, MCHR2, MC1R | PDK4 2356/4885GRM5 215/4885GRM1 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.